Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II purinostat mesylate for relapsed/refractory DLBCL
ChiCTR2500098231Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of purinostat in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Started Mar 2025; status: completed.
02
Drugs
purinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2500098231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098231.